Search

New from AVAC

This round up offers on-the-ground tools for rolling out injectable lenacapavir; updates on AVAC’s court case on foreign assistance; resources on the state of defending rights to health and inclusion for key populations; a look at AVAC’s Advocacy Navigator program; updates on DPP at ICFP; and resources for cure research and the prevention of STIs.

Navigating Change

Advocacy and HIV Cure Research Agenda

Advances over the past ten years toward an HIV cure have moved cure research from a dream to an attainable goal. The field has learned more about the power of the innate immune system through individuals who have controlled their virus, either spontaneously or post-treatment, and these insights have spurred innovation and momentum in cure research.

Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.

The Dual Prevention Pill Introduction Plan

Global Health Watch: South Africa registers LEN for PrEP, US global health MoU, EU may cut $ for Gavi + Global Fund, new Lancet SRH series

This week, South Africa became the first African nation to register injectable lenacapavir (LEN) for PrEP. The US released a draft global health “Memorandum of Understanding” (MoU) with serious omissions related to HIV prevention and community engagement; and a leaked document indicates that the European Union may cut future funding to Gavi and the Global Fund. And just as this issue was being published, The Lancet issued a new series, Innovations in Sexual and Reproductive Health.

Sexually Transmitted Infections: ‘Self-testing’ versus ‘self-collection’: the critical role of consistent language in the field of STI diagnostics

This editorial from AVAC’s Alison Footman and colleagues makes the case for precise and consistent language around self-testing and self-collection. because clarity impacts policy, expectations, and access.

An Overview of Lenacapavir for PrEP Trials

The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.

Moving a Product to the Real World

To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.

Transforming HIV Prevention in 2025

Enormous changes are underway in HIV prevention and across global health. It’s our work to vigilantly track impacts on research, development and delivery and to call out inequity, greed, misinformation, and misguided assumptions. Here are three questions advocates are asking now along with resources to support this work.